McPhadden Samac Tuovi LLP

McPhadden Samac Tuovi LLP

December 17, 2015 17:07 ET

Toronto Law Firm McPhadden Samac Tuovi Investigating Vytorin and Zetia Heart and Cancer Claims

TORONTO, ONTARIO--(Marketwired - Dec. 17, 2015) - Toronto class action law firm McPhadden Samac Tuovi LLP announces that it is investigating possible claims against Merck in relation to its blockbuster drugs Vytorin and Zetia. Zetia has been marketed in Canada under the name Ezetrol.

Vytorin is a drug combination composed of Zetia and Simvastatin used for the treatment of dyslipidemia. Dyslipidemia is an abnormal amount of lipids such as cholesterol and/or fat.

Sales of Vytorin in 2014 were in excess of $1.5 billion and sales of Zetia in 2014 were $2.65 billion.

On December 14, a committee at the FDA rejected Merck's application to expand the approved uses of the two drugs. Missing clinical trial information was one of the factors in the committee's rejection of expanded approved uses.

The missing information raises questions about how the information came to be lost and whether the missing information would have had a bearing on existing approved uses or on the warnings provided in respect of currently approved uses, particularly as regards heart and cancer events.

MCST would like to speak to anyone who has suffered such an event after taking Vytorin and Zetia. MCST would also like to speak to any Merck employees or representatives with knowledge about the missing information and marketing efforts for those drugs in Canada. People with information or who have suffered a heart event or developed cancer may contact the law firm in confidence at 416-601-1020 or at bmcphadden@mcst.ca

Contact Information